Full Breakdown
Eli Lilly's Orforglipron Shows Promise in Phase 3 Trials for Type 2 Diabetes
10/18/2025, 11:42:13 AM
Overview of Phase 3 Trials
Eli Lilly's investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, orforglipron, has demonstrated significant efficacy in two pivotal Phase 3 trials, ACHIEVE-2 and ACHIEVE-5. These trials assessed orforglipron's potential as a foundational therapy for type 2 diabetes (T2D) by comparing it with established treatments. The results indicate that orforglipron may soon alter first-line treatment protocols for T2D.
Key Findings from ACHIEVE Trials
In the ACHIEVE-2 trial, orforglipron was compared to dapagliflozin, a commonly used sodium-glucose cotransporter-2 (SGLT-2) inhibitor. The study revealed that orforglipron led to a reduction in hemoglobin A1c (HbA1c) levels by up to 1.7%, compared to a 0.8% reduction with dapagliflozin. Similarly, the ACHIEVE-5 trial, which evaluated orforglipron in conjunction with insulin glargine, showed an HbA1c reduction of up to 2.1%. Both trials met their primary and secondary endpoints, including improvements in body weight and cardiovascular risk factors.
Safety and Tolerability
The overall safety profile of orforglipron was consistent with previous studies, with gastrointestinal issues being the most common adverse events reported. No significant hepatic safety concerns were noted, reinforcing the drug's tolerability.
Official Statements & Responses
Jeff Emmick, MD, PhD, senior vice president of product development at Lilly Cardiometabolic Health, stated, "Orforglipron has now demonstrated superiority over two active comparators in clinical trials for type 2 diabetes." He emphasized the drug's potential to become a new standard of care for individuals living with T2D.
Why It Matters
The introduction of orforglipron represents a significant advancement in diabetes treatment, particularly as it offers a non-peptide, once-daily oral option. This could enhance patient adherence and improve overall treatment outcomes, addressing a critical need in diabetes management.
What's Next
Eli Lilly plans to seek global regulatory approval for orforglipron in T2D by 2026 and aims to explore its use in obesity indications later this year. Detailed results from the ACHIEVE trials are expected to be presented at future medical meetings and published in peer-reviewed journals.
Criticism & Opposition
While the results are promising, some experts caution that further long-term studies are necessary to fully understand the implications of orforglipron's use in diverse patient populations. Concerns about the long-term safety and efficacy of new diabetes treatments remain a topic of discussion among healthcare professionals.
Verbatim Quotes
- “Orforglipron has now demonstrated superiority over 2 active comparators in clinical trials for type 2 diabetes,” — Jeff Emmick, MD, PhD, Eli Lilly
- “In ACHIEVE-2, orforglipron outperformed dapagliflozin, a commonly used SGLT-2 therapy, and in ACHIEVE-3, showed greater efficacy than oral semaglutide. The findings from ACHIEVE-5 add to this momentum, showing significant A 1c reduction and weight loss when used in combination with titrated basal insulin. Together, these results reinforce orforglipron's potential to become a new standard of care for people living with type 2 diabetes.” — Jeff Emmick, MD, PhD, Eli Lilly
